Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCCC NASDAQ:CMPS NASDAQ:IMTX NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$3.67+4.1%$2.89$1.21▼$3.95$405.24M2.772.47 million shs902,674 shsCMPSCompass Pathways$11.92+2.8%$7.54$2.25▼$12.24$1.61B2.393.62 million shs2.50 million shsIMTXImmatics$11.53+4.2%$10.55$4.93▼$12.41$1.54B1.31451,116 shs90,173 shsURGNUrogen Pharma$28.95-3.1%$22.51$3.61▼$32.37$1.41B1.58817,739 shs144,588 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics+7.32%-3.03%+12.82%+62.96%+158.82%CMPSCompass Pathways+6.62%+9.13%+25.30%+43.98%+167.05%IMTXImmatics-1.43%-0.98%-1.07%+9.94%+116.02%URGNUrogen Pharma-1.13%+0.67%+19.38%+41.81%+616.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$3.67+4.1%$2.89$1.21▼$3.95$405.24M2.772.47 million shs902,674 shsCMPSCompass Pathways$11.92+2.8%$7.54$2.25▼$12.24$1.61B2.393.62 million shs2.50 million shsIMTXImmatics$11.53+4.2%$10.55$4.93▼$12.41$1.54B1.31451,116 shs90,173 shsURGNUrogen Pharma$28.95-3.1%$22.51$3.61▼$32.37$1.41B1.58817,739 shs144,588 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics+7.32%-3.03%+12.82%+62.96%+158.82%CMPSCompass Pathways+6.62%+9.13%+25.30%+43.98%+167.05%IMTXImmatics-1.43%-0.98%-1.07%+9.94%+116.02%URGNUrogen Pharma-1.13%+0.67%+19.38%+41.81%+616.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCCCC4 Therapeutics 2.57Moderate Buy$7.75111.46% UpsideCMPSCompass Pathways 2.93Moderate Buy$20.5872.68% UpsideIMTXImmatics 2.67Moderate Buy$19.0064.79% UpsideURGNUrogen Pharma 2.80Moderate Buy$36.6726.66% UpsideCurrent Analyst Ratings BreakdownLatest CCCC, CMPS, URGN, and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026CMPSCompass Pathways Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026CMPSCompass Pathways HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026CMPSCompass Pathways Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/19/2026IMTXImmatics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.005/18/2026URGNUrogen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/15/2026CMPSCompass Pathways Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $20.005/14/2026CMPSCompass Pathways Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$16.00 ➝ $17.005/14/2026CMPSCompass Pathways Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$21.00 ➝ $22.005/13/2026CMPSCompass Pathways BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.005/11/2026URGNUrogen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.005/11/2026URGNUrogen Pharma LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$43.00(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCCCC4 Therapeutics$35.95M11.27N/AN/A$2.12 per share1.73CMPSCompass PathwaysN/AN/AN/AN/A$2.42 per shareN/AIMTXImmatics$54.60M28.31N/AN/A$3.98 per share2.90URGNUrogen Pharma$109.79M12.85N/AN/A($2.55) per share-11.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCCCC4 Therapeutics-$104.99M-$1.19N/AN/AN/A-297.76%-50.68%-33.22%8/6/2026 (Estimated)CMPSCompass Pathways-$287.86M-$3.15N/AN/AN/AN/A-31.07%-11.40%7/30/2026 (Estimated)IMTXImmatics-$222.26M-$1.99N/AN/AN/A-572.35%-47.36%-39.35%N/AURGNUrogen Pharma-$153.49M-$2.75N/A20.68N/A-94.83%N/A-62.85%8/6/2026 (Estimated)Latest CCCC, CMPS, URGN, and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026CMPSCompass Pathways-$0.45-$0.30+$0.15-$0.30N/AN/A5/12/2026Q1 2026CCCCC4 Therapeutics-$0.2506-$0.20+$0.0506-$0.20$4.42 million$6.15 million5/12/2026Q1 2026IMTXImmatics-$0.42-$0.50-$0.08-$0.50$9.79 million$8.81 million5/7/2026Q1 2026URGNUrogen Pharma-$0.4824-$0.47+$0.0124-$0.47$44.83 million$50.96 million3/24/2026Q4 2025CMPSCompass Pathways-$0.41-$1.00-$0.59-$1.00N/AN/A3/5/2026Q4 2025IMTXImmatics-$0.48-$0.34+$0.14-$0.34$12.18 million$23.18 million3/2/2026Q4 2025URGNUrogen Pharma-$0.66-$0.54+$0.12-$0.54$39.92 million$37.84 million2/26/2026Q4 2025CCCCC4 Therapeutics-$0.43-$0.18+$0.25-$0.18$4.48 million$11.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCCCCC4 TherapeuticsN/AN/AN/AN/AN/ACMPSCompass PathwaysN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCCCC4 TherapeuticsN/A9.009.00CMPSCompass Pathways0.153.323.32IMTXImmaticsN/A8.788.78URGNUrogen PharmaN/A4.694.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCCCC4 Therapeutics78.81%CMPSCompass Pathways46.19%IMTXImmatics64.41%URGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipCCCCC4 Therapeutics5.60%CMPSCompass Pathways2.82%IMTXImmatics3.30%URGNUrogen Pharma4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCCCC4 Therapeutics150110.57 million104.38 millionOptionableCMPSCompass Pathways120134.95 million131.14 millionOptionableIMTXImmatics260134.07 million129.65 millionOptionableURGNUrogen Pharma20048.72 million46.43 millionOptionableCCCC, CMPS, URGN, and IMTX HeadlinesRecent News About These CompaniesAnalysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN) and CervoMed (CRVO)May 18, 2026 | theglobeandmail.comUroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer TranscriptMay 17, 2026 | seekingalpha.comUroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBCMay 15, 2026 | globenewswire.comUrogen Pharma (NASDAQ:URGN) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 15, 2026 | americanbankingnews.comUroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION TrialMay 13, 2026 | globenewswire.comURGN Share News TodayMay 12, 2026 | uk.investing.comUrogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?May 11, 2026 | zacks.comUrogen Pharma (NASDAQ:URGN) Now Covered by Analysts at LADENBURG THALM/SH SHMay 11, 2026 | marketbeat.comAssessing UroGen Pharma (URGN) Valuation After Q1 2026 Earnings Beat And Zusduri Launch MomentumMay 8, 2026 | finance.yahoo.comUroGen Pharma Ltd. (NASDAQ:URGN) Q1 2026 Earnings Call TranscriptMay 8, 2026 | insidermonkey.comUrogen Pharma (NASDAQ:URGN) Sets New 1-Year High Following Analyst UpgradeMay 8, 2026 | marketbeat.comUroGen Pharma Earnings Call Highlights ZUSDURI SurgeMay 7, 2026 | tipranks.comUroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027May 7, 2026 | seekingalpha.comUrogen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Oppenheimer Analyst SaysMay 7, 2026 | marketbeat.comUroGen Pharma to Present at Upcoming Investor ConferencesMay 7, 2026 | globenewswire.comUrogen Pharma Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comUroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comUrogen Pharma (NASDAQ:URGN) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSMay 6, 2026 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Trading Up 14% on Better-Than-Expected EarningsMay 6, 2026 | marketbeat.comUrogen Pharma (URGN) Reports Q1 Loss, Beats Revenue EstimatesMay 6, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026These 3 Psychedelic Stocks Activated After Trump's Executive OrderBy Nathan Reiff | April 27, 2026CCCC, CMPS, URGN, and IMTX Company DescriptionsC4 Therapeutics NASDAQ:CCCC$3.66 +0.15 (+4.12%) As of 01:00 PM Eastern This is a fair market value price provided by Massive. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Compass Pathways NASDAQ:CMPS$11.92 +0.33 (+2.85%) As of 12:59 PM Eastern This is a fair market value price provided by Massive. Learn more.Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Immatics NASDAQ:IMTX$11.53 +0.47 (+4.25%) As of 12:59 PM Eastern This is a fair market value price provided by Massive. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Urogen Pharma NASDAQ:URGN$28.95 -0.93 (-3.11%) As of 01:00 PM Eastern This is a fair market value price provided by Massive. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Lowe's Finds Support at $215 After Q1 Earnings Sell-Off Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
